Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

SUNPHARMA's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 2.824000
forwardPE 28.804716
debtToEquity 5.517000
earningsGrowth 0.256000
revenueGrowth 0.128000
grossMargins 0.802540
operatingMargins 0.188340
trailingEps 47.800000
forwardEps 64.669970

SUNPHARMA's current ratio being 2.824 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
SUNPHARMA's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
With earnings and revenue growth in positive territory, SUNPHARMA is projected to expand its business. This strong financial performance suggests the company will continue to grow, as increased profitability and sales drive future success.
Sun Pharmaceutical Industries Limited's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that Sun Pharmaceutical Industries Limited is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

Throughout its recent performance, SUNPHARMA's price has been consistently close to the lower range of projected values. This suggests that the company may face challenges in achieving higher valuations in the eyes of investors.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


Analysts have shown a buy bias for Sun Pharmaceutical Industries Limited, marking it as a favorable investment option. This could inspire investors to see Sun Pharmaceutical Industries Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.